Kazia Therapeutics Ltd ADR (KZIA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 1 | 15 | 0 | 0 | 2 | 0 | 0 | - |
| Operating profit | AUD m | -14 | -18 | ||||||
| Net profit | AUD m | -12 | -8 | -25 | -20 | -27 | -21 | -22 | - |
| EPS reported | AUD | -18.90 | -10.35 | ||||||
| Operating cashflow per share | AUD | -12.12 | -4.24 | ||||||
| Capex per share | AUD | 0.00 | 1.33 | ||||||
| FCF per share | AUD | -12.12 | -2.91 | ||||||
| Free cash flow | AUD m | -13 | -9 | ||||||
| Net debt | AUD m | -4 | -69 | ||||||
| Book value equity | AUD m | -8 | - | ||||||
| Book value per share | AUD | -7.58 | 14.88 | ||||||
| Number of shares | m | 1.1 | 3.12 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.26 | 1.28 | ||||||
| P/S LTM | x | 248.45 | 529.42 | ||||||
| P/FCF LTM | x | -0.79 | -1.15 | ||||||
| EV/EBITDA LTM | x | -0.49 | -0.36 | ||||||
| EV/Sales LTM | x | 154.43 | -1,947.74 | ||||||
| Earnings Yield LTM | % | -1.98% | -37.41% | ||||||
| FCF Yield | % | -127.25% | -86.96% | ||||||
| Quality | |||||||||
| ROE | % | +249.39% | -116.86% | ||||||
| ROIC | % | +1.73% | -36.21% | ||||||
| Operating margin | % | -338.50% | -920.86% | ||||||
| Gross margin | % | +100.00% | +100.00% | ||||||
| FCF/Sales | % | -31614.3% | -46038.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -98.18% | -99.15% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -33.53 | -91.93 | ||||||
| Net Debt/EBITDA | x | 0.30 | 3.82 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +3.79% | +0.32% | ||||||
| Net debt/Equity | x | 0.48 | - | ||||||
| Gross debt/equity | x | -0.05 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kazia Therapeutics Ltd ADR (KZIA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free